<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327726</url>
  </required_header>
  <id_info>
    <org_study_id>6075-26-4-2020</org_study_id>
    <nct_id>NCT04327726</nct_id>
  </id_info>
  <brief_title>Effectiveness of Nebulized Dexmedetomidine for Treatment of Obstetric Post-Dural Puncture Headache</brief_title>
  <official_title>Effectiveness of Nebulized Dexmedetomidine for Treatment of Post-Dural Puncture Headache in Parturients Undergoing Elective Cesarean Section Under Spinal Anesthesia: Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postdural puncture headache (PDPH) is a common complication, following neuraxial techniques.
      The obstetric population is particularly prone to PDPH. Therefore, treatment of PDPH is a key
      issue in obstetric anesthesia.

      Dexmedetomidine is a highly selective, centrally acting α2-adrenergic agonist with analgesic
      and anxiolytic effects. Moreover, it decreases cerebral blood flow (CBF) in humans and
      animals secondary to cerebrovascular vasoconstriction. It has been used via the intranasal
      and inhalational routes for many purposes including premedication, sedation and postoperative
      analgesia. Because of its desirable properties, we hypothesized that dexmedetomidine
      nebulization could be effective in the treatment of patients suffering from PDPH after
      caesarean section.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-Dural puncture headache (PDPH) is a well-known common devastating complication of
      subarachnoid block. Despite the decreasing incidences of PDPH over the last years due to the
      advancement in the design and smaller size of spinal needles, PDPH remains to be a common
      complication in post-partum patients. Female gender, typically pregnant females, young age,
      low body mass index, dilutional anemia, and the preference of neuraxial anesthesia for
      Cesarean Section renders obstetric patients to be more exposed to PDPH. Consequently,
      treating this complication is of paramount importance in obstetric anesthesia.

      The cause of PDPH is not entirely known but there is a considerable evidence support the
      explanation of the low cerebrospinal fluid (CSF) pressure resulting from continuous CSF leak
      through the tear in meninges that exceeds the CSF production rate as a main cause of PDPH. As
      little as 10% CSF volume loss could induce PDPH from the traction on the pain sensitive
      intracranial structures in the upright position combined with reflex vasodilatation. Several
      treatment options have been proposed which are usually consisting of bed rest in supine
      position, fluid therapy, analgesics, sumatriptan and caffeine. Epidural blood patch remained
      the gold standard therapy but it is an invasive technique.

      Dexmedetomidine (Dex) is a highly selective centrally acting α2-adrenoreceptor agonist that
      produces cooperative sedation, anxiolysis, and analgesia with minimal respiratory depression.
      Moreover it was found to attenuate the stress and inflammatory response to anesthetic and
      surgical procedures. Stimulation of α2-receptors in substantia gelatinosa of the dorsal horn
      leads to suppression of nociceptive neurons firing and inhibition of substance-P release
      also, its stimulation in the locus coeruleus area which is known to be a significant
      nociceptive transmission modulator terminates pain signals transmission resulting in
      analgesia. Additionally, an existing literature supports that Dex decreases cerebral blood
      flow (CBF) in humans and animals secondary to cerebrovascular vasoconstriction. Thus, the use
      of Dex might be a useful adjunct in certain situations that require cerebral vasoconstriction
      together with analgesia such as PDPH. The present study will be undertaken to test this
      hypothesis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants will not be aware of their group assignment, and the medications will be prepared by an anesthetist who is not involved in the study. The anesthetist who will assess the participants after the intervention is blinded to the group allocation and single experienced operator who is unaware of patient group and study purpose will perform all Trans-Cranial Doppler (TCD) measurements.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>visual analogue score (VAS)</measure>
    <time_frame>24 hour</time_frame>
    <description>using the 10-cm visual analogue score (VAS) where score 0 is no headache and 10 is the worst imaginable headache with 1-3 classified as mild, 4-6 moderate, and 7-10 severe our aim to get VAS &lt;/= 3 at 24 hour from starting treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lybecker headache classification score</measure>
    <time_frame>24 hour</time_frame>
    <description>our aim to get Lybecker score &lt; 2 at 24hour following treatment Lybecker et al. classification of PDPH score 1: Mild PDPH where daily activities slightly restricted. Patient is not bedridden.
No associated symptoms*. Score 2:Moderate: Daily activities significantly restricted and most of the day patient is bedridden with or without associated symptoms.
Score 3:Severe Daily activities completely restricted, patient is bedridden all the day and always with associated symptoms Associated symptoms include: Nausea, vomiting, vertigo, dizziness, tinnitus Photophobia, diplopia, and neck stiffness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the effects of nebulized dexmedetomidine on cerebral blood flow by using Trans-Cranial Doppler (TCD)</measure>
    <time_frame>72 hours</time_frame>
    <description>TCD measurements (mean flow velocity, pulsatility index) will be performed at 0, 24, 48, 72hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects related to nebulized Dexmedetomidine</measure>
    <time_frame>72 hours</time_frame>
    <description>occurrence of any adverse effects (Hypotension, bradycardia, sedation) related to nebulized Dexmedetomidine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Post-Dural Puncture Headache</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>received ultrasonic nebulization of 4mL 0.9% saline twice daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received ultrasonic nebulization of 1 µg/kg dexmedetomidine diluted in 4mL 0.9% saline twice daily for 3 days. The intervention will be continued until achieving a VAS score ≤3 and Lybecker et al. classification score &lt;2 and or for a maximum of 72 hours. Patients in this group who achieved the target scores before 72 hours will be given 4ml of saline 0.9% nebulization to maintain blinding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Nebulization</intervention_name>
    <description>ultrasonic nebulization of 1 µg/kg dexmedetomidine for PDPH treatment</description>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.9% Saline Nebulization</intervention_name>
    <description>nebulization of 4mL 0.9% saline</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-partum females diagnosed with PDPH after elective caesarean section under spinal
             anesthesia and with visual analogue score (VAS) ≥ 4 and Lybecker et al. classification
             score ≥2.

          -  Age 21- 40 years old.

          -  ASA I and ASA II.

          -  Accepted mental state of the patient.

        Exclusion Criteria:

          -  Patient refusal.

          -  ASA Grade III and IV.

          -  Emergent caesarean section.

          -  Inadequate temporal window.

          -  Hypertensive disorders of the pregnancy.

          -  Atrial fibrillation.

          -  History of allergy to local anesthetics.

          -  History of chronic headache, migraine, convulsions, and cerebrovascular accident.

          -  Contraindication to spinal anesthesia: coagulopathy, infection at site of injection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherif M Mowafy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesia and Surgical Intensive Care Department, Faculty of Medicine, Zagazig University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shereen E Abd Ellatif, MD</last_name>
    <role>Study Director</role>
    <affiliation>Anesthesia and Surgical Intensive Care Department, Faculty of Medicine, Zagazig University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherif M Mowafy, MD</last_name>
    <phone>01003523374</phone>
    <phone_ext>002</phone_ext>
    <email>sherifmowafy2012@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>shereen E Abd Ellatif, MD</last_name>
    <phone>01007948840</phone>
    <phone_ext>002</phone_ext>
    <email>shosh.again@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zagazig University Hospitals</name>
      <address>
        <city>Zagazig</city>
        <state>Sharkia</state>
        <zip>44519</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherif M Mowafy, MD</last_name>
      <phone>01003523374</phone>
      <phone_ext>002</phone_ext>
      <email>sherifmowafy2012@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>shereen E Abd Ellatif, MD</last_name>
      <phone>01007948840</phone>
      <phone_ext>002</phone_ext>
      <email>shosh.again@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Sachs A, Smiley R. Post-dural puncture headache: the worst common complication in obstetric anesthesia. Semin Perinatol. 2014 Oct;38(6):386-94. doi: 10.1053/j.semperi.2014.07.007. Epub 2014 Aug 19. Review.</citation>
    <PMID>25146108</PMID>
  </reference>
  <reference>
    <citation>Bardon J, LE Ray C, Samama CM, Bonnet MP. Risk factors of post-dural puncture headache receiving a blood patch in obstetric patients. Minerva Anestesiol. 2016 Jun;82(6):641-8. Epub 2015 Jul 29.</citation>
    <PMID>26222393</PMID>
  </reference>
  <reference>
    <citation>FitzGerald S, Salman M. Postdural puncture headache in obstetric patients. Br J Gen Pract. 2019 Apr;69(681):207-208. doi: 10.3399/bjgp19X702125.</citation>
    <PMID>30923161</PMID>
  </reference>
  <reference>
    <citation>Shah A, Bhatia PK, Tulsiani KL. Post dural puncture headache in caesarean section-a comparative study using 25G Quincke, 27G Quincke and 27G Whitacre needle. Indian J Anaesth 2002; 46(5):373-377.</citation>
  </reference>
  <reference>
    <citation>Turnbull DK, Shepherd DB. Post-dural puncture headache: pathogenesis, prevention and treatment. Br J Anaesth. 2003 Nov;91(5):718-29. Review.</citation>
    <PMID>14570796</PMID>
  </reference>
  <reference>
    <citation>Amorim JA, Gomes de Barros MV, Valença MM. Post-dural (post-lumbar) puncture headache: risk factors and clinical features. Cephalalgia. 2012 Sep;32(12):916-23. doi: 10.1177/0333102412453951. Epub 2012 Jul 27.</citation>
    <PMID>22843225</PMID>
  </reference>
  <reference>
    <citation>Uyar Türkyilmaz E, Eryilmaz NC, Güzey NA, Moraloğlu Ö. [Bilateral greater occipital nerve block for treatment of post-dural puncture headache after caesarean operations]. Rev Bras Anestesiol. 2016 Sep-Oct;66(5):445-50. doi: 10.1016/j.bjan.2015.12.001. Epub 2016 Jul 18. Portuguese.</citation>
    <PMID>27445257</PMID>
  </reference>
  <reference>
    <citation>Tsaousi GG, Bilotta F. Is dexmedetomidine a favorable agent for cerebral hemodynamics? Indian J Crit Care Med. 2016 Jan;20(1):1-2. doi: 10.4103/0972-5229.173675.</citation>
    <PMID>26955209</PMID>
  </reference>
  <reference>
    <citation>Tang C, Huang X, Kang F, Chai X, Wang S, Yin G, Wang H, Li J. Intranasal Dexmedetomidine on Stress Hormones, Inflammatory Markers, and Postoperative Analgesia after Functional Endoscopic Sinus Surgery. Mediators Inflamm. 2015;2015:939431. doi: 10.1155/2015/939431. Epub 2015 Jun 25.</citation>
    <PMID>26199465</PMID>
  </reference>
  <reference>
    <citation>Jaakola ML, Salonen M, Lehtinen R, Scheinin H. The analgesic action of dexmedetomidine--a novel alpha 2-adrenoceptor agonist--in healthy volunteers. Pain. 1991 Sep;46(3):281-5.</citation>
    <PMID>1684653</PMID>
  </reference>
  <reference>
    <citation>Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001 Jan;14(1):13-21.</citation>
    <PMID>16369581</PMID>
  </reference>
  <reference>
    <citation>Gerlach AT, Dasta JF. Dexmedetomidine: an updated review. Ann Pharmacother. 2007 Feb;41(2):245-52. Epub 2007 Feb 13. Review. Erratum in: Ann Pharmacother. 2007 Mar;41(3):530-1.</citation>
    <PMID>17299013</PMID>
  </reference>
  <reference>
    <citation>Drummond JC, Dao AV, Roth DM, Cheng CR, Atwater BI, Minokadeh A, Pasco LC, Patel PM. Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans. Anesthesiology. 2008 Feb;108(2):225-32. doi: 10.1097/01.anes.0000299576.00302.4c.</citation>
    <PMID>18212567</PMID>
  </reference>
  <reference>
    <citation>Kumar A, Kumar A, Sinha C, Anant M, Singh JK. Dexmedetomidine nebulization: an answer to post-dural puncture headache? Int J Obstet Anesth. 2019 Nov;40:155-156. doi: 10.1016/j.ijoa.2019.06.004. Epub 2019 Jun 19.</citation>
    <PMID>31345663</PMID>
  </reference>
  <reference>
    <citation>Lybecker H, Djernes M, Schmidt JF. Postdural puncture headache (PDPH): onset, duration, severity, and associated symptoms. An analysis of 75 consecutive patients with PDPH. Acta Anaesthesiol Scand. 1995 Jul;39(5):605-12.</citation>
    <PMID>7572008</PMID>
  </reference>
  <reference>
    <citation>Bathala L, Mehndiratta MM, Sharma VK. Transcranial doppler: Technique and common findings (Part 1). Ann Indian Acad Neurol. 2013 Apr;16(2):174-9. doi: 10.4103/0972-2327.112460.</citation>
    <PMID>23956559</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 28, 2020</study_first_submitted>
  <study_first_submitted_qc>March 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Sherif M. S. Mowafy</investigator_full_name>
    <investigator_title>Lecturer of anesthesia and surgical intensive care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Dural Puncture Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all individual participant data that underlie results in the publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>the individual participant data and any additional supporting information will become available starting 6 months after publication.</ipd_time_frame>
    <ipd_access_criteria>by contacting the study director</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

